DigestRedComo funciona
Red
/
Empresas
Ge
No verificado

Genmab A/S

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosOncologíaSalud

29 Comunicados de prensa

Ver todos los comunicados de prensa
16/01/2026
Oncología
Higiene alimentaria
Salud
Medicina - Varios
Farmacéutica
Biotecnología
Industria
Genmab Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Fuente
Genmab A/S
Editor
Business Wire
1.00
0
07/01/2026
Ciencia
Sanidad
Farmacéutica
Oncología
Técnica
Medicina - Varios
Biotecnología
Tecnología
Salud
Mercado laboral
Industria
Genmab Partners with Anthropic to Accelerate Research and Development Through Agentic Artificial Intelligence
Fuente
Genmab A/S
Editor
Business Wire
1.00
0
29/12/2026
Biotecnología
Sanidad
Salud
Medicina - Varios
Genmab Portfolio Prioritization Update
Fuente
Genmab A/S
Editor
Business Wire
1.00
0
12/12/2025
Mercado de valores
Oncología
Salud
Medicina - Varios
Farmacéutica
Cardiología
Biotecnología
Genmab Announces Completion of Tender Offer for Outstanding Common Shares of Merus N.V. and Commencement of Subsequent Offering Period
Fuente
Genmab A/S
Editor
Business Wire
1.00
0
08/12/2025
Eventos
Ferias y Congresos
Industria
Oncología
Salud
Medicina - Varios
Farmacéutica
Cardiología
Biotecnología
Genmab Announces New Data from Phase 1b/2 EPCORE® CLL-1 Highlighting Potential of Epcoritamab as Monotherapy and in Combination for Patients with Richter Transformation (RT)
Fuente
Genmab A/S
Editor
Business Wire
1.00
0
07/12/2025
Industria
Oncología
Salud
Medicina - Varios
Farmacéutica
Cardiología
Biotecnología
Genmab Presents Pivotal Phase 3 Data from EPCORE® FL-1 Trial Demonstrating Clinical Benefit of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide (R2) in Patients with Relapsed or Refractory Follicular Lymphoma
Fuente
Genmab A/S
Editor
Business Wire
1.00
0
06/12/2025
Eventos
Industria
Ciencia
Cardiología
Biotecnología
Farmacéutica
Oncología
Salud
Medicina - Varios
Genmab Announces Data From Multiple Clinical Trials Showing Treatment with Fixed-Duration Epcoritamab Led to Remissions in First-Line Diffuse Large B-Cell Lymphoma (DLBCL) and Follicular Lymphoma (FL)
Fuente
Genmab A/S
Editor
Business Wire
1.00
0
18/11/2025
Higiene alimentaria
Salud
Medicina - Varios
Sanidad
Farmacéutica
Biotecnología
Industria
Genmab Announces EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide Approved by the U.S. Food and Drug Administration for the Treatment of Relapsed or Refractory Follicular Lymphoma
Fuente
Genmab A/S
Editor
Business Wire
1.00
0
03/11/2025
Ciencia
Biotecnología
Farmacéutica
Oncología
Sanidad
Salud
Medicina - Varios
Industria
Genmab to Showcase Latest Blood Cancer Treatment Advancements at 2025 American Society of Hematology (ASH) Annual Meeting
Fuente
Genmab A/S
Editor
Business Wire
1.00
0
29/09/2025
Biotecnología
Salud
Oncología
Medicina - Varios
Mercado de valores
Genmab to Acquire Merus, Expanding Late-Stage Pipeline and Accelerating into a Wholly Owned Model
Fuente
Genmab A/S
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0